Acamprosate
Active ingredient: Acamprosate Calcium
In short: Acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that
What is Acamprosate used for?
Acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support.
The efficacy of acamprosate calcium delayed-release tablets in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium delayed-release tablets treatment. The efficacy of acamprosate calcium delayed-release tablets in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed.
Acamprosate dosage
The recommended dose of acamprosate calcium delayed-release tablets is two 333 mg tablets (each dose should total 666 mg) taken three times daily. A lower dose may be effective in some patients.
Although dosing may be done without regard to meals, dosing with meals was employed during clinical trials and is suggested in those patients who regularly eat three meals daily.
Treatment with acamprosate calcium delayed-release tablets should be initiated as soon as possible after the period of alcohol withdrawal, when the patient has achieved abstinence, and should be maintained if the patient relapses. Acamprosate calcium delayed-release tablets should be used as part of a comprehensive psychosocial treatment program.
For patients with moderate renal impairment (creatinine clearance of 30 mL/min to 50 mL/min), a starting dose of one 333 mg tablet taken three times daily is recommended. Acamprosate calcium delayed-release tablets are contraindicated in patients with severe renal impairment (creatinine clearance of ⤠30 mL/min)
[see
Contraindications (4.2),
Warnings and Precautions (5.1),
Use in Specific Populations (8.6),
and
Clinical Pharmacology (12.3)]
.
How to take Acamprosate ā instructions & advice from the label
Physicians are advised to discuss the following issues with patients for whom they prescribe acamprosate calcium.
Renal Impairment
A lower dose is recommended for patients with moderate renal impairment. Acamprosate calcium is contraindicated in patients with severe renal impairment (creatinine clearance of ⤠30 mL/min)
[
see
Dosage and Administration (2.1),
Contraindications (4.2),
Warnings and Precautions (5.1)and
Use in Specific Populations (8.6)
].
Suicidality and Depression
Families and caregivers of patients being treated with acamprosate calcium should be alerted to the need to monitor patients for the emergence of symptoms of depression or suicidality, and to report such symptoms to the patient's health care provider
.
Alcohol Withdrawal
Use of acamprosate calcium does not eliminate or diminish withdrawal symptoms
.
Pregnancy and Breast Feeding
Advise patients to notify their physician if they become pregnant or intend to become pregnant during therapy.
Advise patients to notify their physician if they are breast-feeding. ā¦
Warnings & precautions
Do not take this medicine if: Acamprosate calcium is contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components.
Acamprosate calcium is contraindicated in patients with severe renal impairment (creatinine clearance of ⤠30 mL/min)
[see
Dosage and Administration (2.1),
Warnings and Precautions (5.1),
Use in Specific Populations (8.6),
and
Clinical Pharmacology (12.3)]
.
Treatment with acamprosate calcium in patients with moderate renal impairment (creatinine clearance of 30 mL/min to 50 mL/min) requires a dose reduction
. Acamprosate calcium is contraindicated in patients with severe renal impairment (creatinine clearance of ⤠30 mL/min)
[see
Dosage and Administration (2.1),
Contraindications (4.2),
Use in Specific Populations (8.6),
and
Clinical Pharmacology (12.3)].
In controlled clinical trials of acamprosate calcium, adverse events of a suicidal nature (suicidal ideation, suicide attempts, completed suicides) were infrequent overall, but were more common in acamprosate calcium-treated patients than in patients treated with placebo (1.4% vs. 0.5% in studies of 6 months or less; 2.4% vs. 0.8% in year-long studies). Completed suicides occurred in 3 of 2,272 (0.13%) patients in the pooled acamprosate group from all controlled studies and 2 of 1,962 patients (0.10%) in the placebo group. Adverse events coded as "depression" were reported at similar rates in acamprosate calcium-treated and placebo-treated patients. Although many of these events occurred in the context of alcohol relapse, and the interrelationship between alcohol dependence, depression and suicidality is well-recognized and complex, no consistent pattern of relationship between the clinical course of recovery from alcoholism and the emergence of suicidality was identified. ā¦
Acamprosate side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Clinically significant serious adverse reactions associated with acamprosate calcium described elsewhere in labeling include suicidality and depression and acute kidney failure
.
The adverse event data described below reflect the safety experience in over 7,000 patients exposed to acamprosate calcium for up to one year, including over 2,000 acamprosate calcium-exposed patients who participated in placebo-controlled trials.
Adverse Events Leading to Discontinuation
In placebo-controlled trials of 6 months or less, 8% of acamprosate calcium-treated patients discontinued treatment due to an adverse event, as compared to 6% of patients treated with placebo. In studies longer than 6 months, the discontinuation rate due to adverse events was 7% in both the placebo-treated and the acamprosate calcium-treated patients. Only diarrhea was associated with the discontinuation of more than 1% of patients (2% of acamprosate calcium-treated vs. 0.7% of placebo-treated patients). ā¦
Drug interactions
Acamprosate does not affect the pharmacokinetics of alcohol. The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed
.
About this medicine
Acamprosate calcium delayed-release tablets are supplied as an enteric-coated tablet for oral administration. Acamprosate calcium is a synthetic compound with a chemical structure similar to that of the endogenous amino acid homotaurine, which is a structural analogue of the amino acid neurotransmitter γ-aminobutyric acid and the amino acid neuromodulator taurine. Its chemical name is calcium acetylaminopropane sulfonate. Its chemical formula is C
10H
20N
2O
8S
2Ca and molecular weight is 400.48 g/mol. Its structural formula is:
Acamprosate calcium, USP is white or almost white powder. It is freely soluble in water, practically insoluble in alcohol and in methylene chloride.
Each acamprosate calcium delayed-release tablet contains acamprosate calcium, USP 333 mg, equivalent to 300 mg of acamprosate. ā¦
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5ebfa8c9-acba-b77e-e063-6294a90ab712. Read the full official label on DailyMed.